Published in Cancer Metastasis Rev on June 01, 2009
Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol (2011) 2.61
Killing cells by targeting mitosis. Cell Death Differ (2012) 1.65
Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis (2012) 1.60
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res (2010) 1.43
8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS One (2009) 1.14
Inhibition of Kinesin-5, a microtubule-based motor protein, as a strategy for enhancing regeneration of adult axons. Traffic (2011) 1.07
Intravital FRET imaging of tumor cell viability and mitosis during chemotherapy. PLoS One (2013) 1.03
Aurora-A inactivation causes mitotic spindle pole fragmentation by unbalancing microtubule-generated forces. Mol Cancer (2011) 1.03
LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling. Br J Cancer (2010) 0.99
KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression. J Cell Biol (2012) 0.99
Novel proteomic approach (PUNCH-P) reveals cell cycle-specific fluctuations in mRNA translation. Genes Dev (2013) 0.99
Growing the growth cone: remodeling the cytoskeleton to promote axon regeneration. Trends Neurosci (2011) 0.93
Kinesin molecular motor Eg5 functions during polypeptide synthesis. Mol Biol Cell (2011) 0.92
High expression of KIF26B in breast cancer associates with poor prognosis. PLoS One (2013) 0.92
Kinesin-5: cross-bridging mechanism to targeted clinical therapy. Gene (2013) 0.92
Cell death signaling and anticancer therapy. Front Oncol (2011) 0.91
The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med (2015) 0.90
Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes. Chem Biol (2013) 0.90
Modular aspects of kinesin force generation machinery. Biophys J (2013) 0.90
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Invest New Drugs (2015) 0.89
Mitosis as an anti-cancer drug target. Chromosoma (2013) 0.88
Targeting the Mitotic Catastrophe Signaling Pathway in Cancer. Mediators Inflamm (2015) 0.86
The crystal structure and biochemical characterization of Kif15: a bifunctional molecular motor involved in bipolar spindle formation and neuronal development. Acta Crystallogr D Biol Crystallogr (2013) 0.86
Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. J Med Chem (2013) 0.84
Rapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells. Cancer Lett (2011) 0.84
Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer. J Exp Clin Cancer Res (2015) 0.83
Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity. J Med Chem (2012) 0.82
Identification of cytoskeleton-associated proteins essential for lysosomal stability and survival of human cancer cells. PLoS One (2012) 0.81
An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene (2016) 0.78
Elevated expression of KIF18A enhances cell proliferation and predicts poor survival in human clear cell renal carcinoma. Exp Ther Med (2016) 0.78
Cenp-E inhibitor GSK923295: Novel synthetic route and use as a tool to generate aneuploidy. Oncotarget (2015) 0.78
Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One (2012) 0.78
Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int J Oncol (2016) 0.78
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity. Bioorg Med Chem (2011) 0.78
An expanding role for cell biologists in drug discovery and pharmacology. Mol Biol Cell (2012) 0.78
Atomic-resolution structure of the CAP-Gly domain of dynactin on polymeric microtubules determined by magic angle spinning NMR spectroscopy. Proc Natl Acad Sci U S A (2015) 0.77
STARD9/Kif16a is a novel mitotic kinesin and antimitotic target. Bioarchitecture (2012) 0.77
Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer. Oncol Lett (2016) 0.75
Upregulate KIF4A Enhances Proliferation, Invasion of Hepatocellular Carcinoma and Indicates poor prognosis Across Human Cancer Types. Sci Rep (2017) 0.75
MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene. Cancer Cell Int (2016) 0.75
Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy. Oncotarget (2017) 0.75
Mitotic inhibitors. J Thorac Oncol (2011) 0.75
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Invest New Drugs (2012) 0.75
Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening. Chem Biol Drug Des (2016) 0.75
Cytoskeleton-Dependent Transport as a Potential Target for Interfering with Post-transcriptional HuR mRNA Regulons. Front Pharmacol (2016) 0.75
Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
KIF7 attenuates prostate tumor growth through LKB1-mediated AKT inhibition. Oncotarget (2017) 0.75
Determination of the Proteomic Response to Lapatinib Treatment using a comprehensive and reproducible ion-current-based proteomics strategy. J Proteom Genom Res (2013) 0.75
Targeting mitotic pathways for endocrine-related cancer therapeutics. Endocr Relat Cancer (2017) 0.75
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 5.65
Mortality in overweight and underweight children with acute myeloid leukemia. JAMA (2005) 2.25
Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.63
The plasma cell signature in autoimmune disease. Arthritis Rheumatol (2014) 1.47
The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem (2002) 1.32
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol (2002) 1.17
Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Sci Transl Med (2014) 1.14
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res (2009) 1.10
B-cell targeted therapeutics in clinical development. Arthritis Res Ther (2013) 1.09
Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res (2007) 1.06
Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol Cancer Ther (2006) 0.97
Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest (2013) 0.97
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol (2011) 0.97
CD19 and CD32b differentially regulate human B cell responsiveness. J Immunol (2014) 0.85
Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol (2011) 0.83
Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain. Biochemistry (2010) 0.83
Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection. J Infect Dis (2012) 0.81
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs (2013) 0.78
Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors. Bioorg Med Chem Lett (2009) 0.78
Targeting the junction of CɛmX and ɛ-migis for the specific depletion of mIgE-expressing B cells. Mol Immunol (2012) 0.77
RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function. J Gen Virol (2013) 0.77
Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha. Mol Med (2008) 0.77
Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase. Bioorg Med Chem Lett (2008) 0.76